Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Memory cytokine enriched natural killer cell therapy - ImmunityBio

Next Previous
Drug Profile

Memory cytokine enriched natural killer cell therapy - ImmunityBio

Alternative Names: M ceNK

Latest Information Update: 21 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator ImmunityBio
  • Class Antineoplastics; Immunotherapies; Natural killer cell therapies
  • Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ovarian cancer
  • Phase I Solid tumours
  • Preclinical Haematological malignancies

Most Recent Events

  • 05 May 2026 ImmunityBio withdrew a phase II trial for Prostate Cancer (Combination therapy) prior to enrolment (SC) (NCT06765954)
  • 05 May 2026 ImmunityBio withdrew a phase II trial for Prostate cancer (Neoadjuvant therapy; Adjuvant therapy, Combination therapy) prior to enrolment (SC) (NCT06765902)
  • 23 Feb 2026 Phase-I development in Solid-tumours(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, First-line therapy, Inoperable/Unresectable) is ongoing in USA (IV, Infusion) (NCT04898543)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top